Pricing Log in Create free account
Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

160.47 5.58 −3.36%
Market cap
$16.2B
P/E
23.0×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) Debt to equity

Alert me on Debt to equity

Neurocrine Biosciences, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 1.0× (fiscal 2017) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 0.0× and in line with the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.2× (13.60%)
FY2020 0.3× 106.66%
FY2019 0.1× (83.10%)
FY2018 0.8× (18.64%)
FY2017 1.0× 49,560.00%
FY2016 0.0× (53.49%)

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
43 more quarters

Against its own ten years

Low 0.0× High 1.0×
Ten-year median 0.0×
Current reading's percentile 36

Debt to equity against peers

Company Debt to equity
NBIX Neurocrine Biosciences, Inc. 0.0×
UTHR United Therapeutics Corporation compare 0.0×
KNSA Kiniksa Pharmaceuticals International, plc compare 0.0×
VTRS Viatris Inc. compare 0.1×
RDY Dr. Reddy's Laboratories Ltd compare 0.2×
HLN Haleon PLC Sponsored ADR compare 0.5×
ELAN Elanco Animal Health Incorporated compare 0.6×
ALKS Alkermes plc compare 0.8×
ZTS Zoetis Inc. compare 2.9×
Drug Manufacturers Specialty & Generic industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on NBIX